Literature DB >> 1503919

Neuroblastoma in the very young child: biological considerations.

J T Kemshead1, K Patel, B Phimister.   

Abstract

Neuroblastoma is one of the childhood malignancies that frustrates both the clinical and scientist. Clearly, some forms of the disease are relatively benign and the patient can expect to be cured. However, even today, Stage 4 neuroblastoma is one of the childhood malignancies where the overall prognosis remains very poor. Despite extensive investigations into the biology of the disease, little has been gleaned about the underlying causes of the tumour and what truly separates good and poor risk disease. Fortunately, patients under the age of one with neuroblastoma often fall into the good risk group. Many people now believe that neuroblastoma is not just one disease, but several. Some forms of the tumours may, in fact, not be truly malignant. The data that has led to this conclusion and the biological characteristics that are associated with the different forms of the neuroblastoma will be reviewed. In addition, a brief outline of new studies which may identify some of the factors associated with the neuroblasts ability to metastasise will be discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503919      PMCID: PMC2149661     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  24 in total

1.  Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1.

Authors:  Y Hayashi; N Kanda; T Inaba; R Hanada; N Nagahara; H Muchi; K Yamamoto
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

2.  Neonatal neuroblastoma.

Authors:  K M Schneider; J M Becker; I H Krasna
Journal:  Pediatrics       Date:  1965-09       Impact factor: 7.124

3.  Cell surface membrane antigen present on neuroblastoma cells but not fetal neuroblasts recognized by a monoclonal antibody (KP-NAC8).

Authors:  T Matsumura; T Sugimoto; T Sawada; T Amagai; S Negoro; J T Kemshead
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

4.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

Authors:  R C Seeger; G M Brodeur; H Sather; A Dalton; S E Siegel; K Y Wong; D Hammond
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

5.  A proposed staging for children with neuroblastoma. Children's cancer study group A.

Authors:  A E Evans; G J D'Angio; J Randolph
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

6.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

7.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.

Authors:  H Shimada; J Chatten; W A Newton; N Sachs; A B Hamoudi; T Chiba; H B Marsden; K Misugi
Journal:  J Natl Cancer Inst       Date:  1984-08       Impact factor: 13.506

8.  Cytogenetic features of human neuroblastomas and cell lines.

Authors:  G M Brodeur; A A Green; F A Hayes; K J Williams; D L Williams; A A Tsiatis
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

9.  N-myc gene product expression in neuroblastoma.

Authors:  H Hashimoto; Y Daimaru; M Enjoji; A Nakagawara
Journal:  J Clin Pathol       Date:  1989-01       Impact factor: 3.411

10.  Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis.

Authors:  B R Oppedal; I Storm-Mathisen; S O Lie; P Brandtzaeg
Journal:  Cancer       Date:  1988-08-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.